

# **The Feasibility of a Smartphone-based Digital Therapeutics for Dysarthria after Stroke (DiDaS): Protocol for a pilot randomized controlled trial**

Yuyoung Kim<sup>1</sup>, Minjung Kim<sup>1</sup>, Jinwoo Kim<sup>1,2</sup>, Tae-Jin Song<sup>3\*</sup>

<sup>1</sup> HCI Lab, Yonsei University, Seoul, South Korea

<sup>2</sup> HAI Corporation, Seoul, South Korea

<sup>3</sup> Department of Neurology, Seoul Hospital, Ewha Womans University College of Medicine, Seoul, South Korea

\* Corresponding author

E-mail: [knstar@ewha.ac.kr](mailto:knstar@ewha.ac.kr) (TJS)

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## Abstract

**Background:** Dysarthria is a motor speech disorder occurring from neurological conditions such as stroke. It leads to serious problems in the intelligibility of patients' speech, affecting their ability to communicate, quality of life, and emotional well-being. While digital therapeutic approaches for rehabilitation of dysarthria are increasing, clinical evidence of the effectiveness of digital therapeutics has been lacking. A mobile application, D-ST01, has the potential to enhance intensive and repetitive speech rehabilitation due to its high treatment accessibility and its incorporation of gamification, tailored feedback, and interactive functions.

**Methods:** In our trial, 60 stroke patients with dysarthria within 30 days following the occurrence of stroke will be recruited. In a 1:1 ratio, participants will be randomly assigned to either the intervention group (using D-ST01 for 60 minutes/day, five days/week along with usual stroke care) or the control group (usual stroke care only). This will be a single-blind study in which researchers will evaluate outcome measurements while masked to treatment allocation. After four weeks of treatment intervention, we will compare speech and psychological changes between the two groups.

**Conclusions:** Our study will evaluate the feasibility of the speech treatment application D-ST01 for patients with post-stroke dysarthria. In addition, it will collect evidence for investigating the future efficacy of a large-scale randomized controlled trial.

**Trial registration number:** ClinicalTrial.gov #NCT05146765

## Introduction

Stroke is one major cause of worldwide mortality and morbidity [1]. Approximately 40% of stroke patients experience disability [2, 3], and more than 50% of acute stroke victims

experience dysarthria [4]. Dysarthria is a neurological motor speech disorder caused by weak, slow, or damaged muscles in the speech-production subsystems [5]. Dysarthria can negatively affect speech intelligibility [5] and communication [6], leading to abnormalities in vocal quality, speed, strength, volume, tone, steadiness, or breath control [5]. Difficulty with communication due to dysarthria after stroke poses a considerable barrier to involvement in social activities and negatively affects the quality of life [7]. It can also lead to emotional difficulties [8], including depression and anxiety.

Intervention for dysarthria involves speech rehabilitation strategies tailored to individual needs and goals [9]. Once emergent medical situations have been settled and the patient is neurologically stabilized, intensive speech treatment is prescribed. The evidence suggests that early, rigorous, and repetitive speech therapy can facilitate neurological recovery [10, 11]. However, treatment adherence may be negatively impacted by the patients due to the tediously repeating nature of current speech treatment [12]. Furthermore, since speech therapy involves a substantial amount of time and effort of speech-language pathologist, patients may face restrictions on therapeutic resources [13]. Currently, only about one-third of patients receive sufficient speech therapy. The frequency of therapy also varies from patient to patient [14]. In this context, the use of digital technologies in speech therapy is continuously expanding due to its potential benefits [15].

Digital therapeutics (DTx) is an “evidence-based intervention using high-quality software to prevent, manage, or treat a medical disorder or disease” [16]. There are several advantages to using DTx for self-rehabilitation of dysarthria. DTx can provide more intensive and extended self-administered speech therapy through a smartphone. Also, DTx can overcome the barriers of in-clinic care by providing personalized treatment remotely regardless of time and place. Gamified rehabilitation is an emerging therapeutic methodology that offers good motivation, feedback, and interactivity [17] and can provide repetitive and goal-oriented programs tailored

to each patient's capabilities [18]. Moreover, conversational technologies can facilitate repetitive tasks by providing objective and quantified performance feedback [19]. These features will encourage patients to actively engage in the management of their health by reducing boredom and poor compliance issues [20]. In addition, post-stroke dysarthria patients can have difficulty visiting outpatient clinics due to mobility problems, insufficient family support, and distance between homes and clinics. Therefore, DTx can expand access to treatment [21]. A mobile system incorporating intensive, repetitive, and functional task-oriented speech treatment that can be initiated even during the acute phase will be an alternative to conventional rehabilitation.

However, evidence of the effectiveness of these treatments, particularly DTx, for post-stroke dysarthria is limited due to a lack of sufficiently powered and controlled trials [22]. We hypothesize that stroke patients with dysarthria treated with a speech therapy application called D-ST01 for four weeks will show more improvement in dysarthria symptoms than those who do not receive treatment with the D-ST01 application. Thus, our goal is to develop and test the feasibility of smartphone-based speech therapy, D-ST01, for a stroke patient with dysarthria.

## Methods

### Study design

This is a single-blind, pilot randomized controlled trial with stroke patients with dysarthria allotted to the intervention or control group (Fig 1 and Fig 2). All participants will be recruited among stroke patients from a single stroke center (Ewha Womans University Seoul Hospital) in South Korea. The trial will be conducted in accordance with the Declaration of Helsinki [23]. We will thoroughly explain the purpose and the terms of the study to the participants and receive written informed consent. The study received ethics approval from the Ewha Womans

University Seoul Hospital Institutional Review Board on December 21, 2021 (Approval number: SEUMC 2021-12-011). The trial is registered with NCT05146765.

**Fig 1. DiDAS pilot trial schedule of enrollment, interventions, and assessments.**

**Fig 2. CONSORT diagram representing participant flow in the study**

## **Inclusion procedure**

The stroke specialist neurologists will screen and enroll participants who meet the eligibility criteria. If a participant meets the eligibility criteria and agrees to participate, a patient information sheet will be delivered to the research coordinator to confirm the patient's eligibility. The principal investigator will inform the study process to the participants, including the various treatment options available for their symptoms and the risks and benefits of the intervention. Then, the principal investigator will obtain consent from the participant following Research Ethics Committee guidance and Clinical Practice Standards. Table 1 presents this study's eligibility criteria.

**Table 1. Inclusion and exclusion criteria.**

<b>Inclusion criteria.</b>
1. Medically stable dysarthria patients, as diagnosed by a stroke specialty neurologist.
2. less than the one-month onset of stroke.
3. Sufficient cognitive function to use speech therapy applications (Mini-Mental State Exam score of 21 $\geq$ ).
4. As judged by the clinician, patients with sufficient ability in vision, hearing, communication skills, and motor skills to participate in this study.
<b>Exclusion criteria</b>
1. Unable to use application or conduct speech assessment due to severe speech impairment.
2. Co-existing progressive neurological conditions such as dementia.
3. Diagnosed with severe mental disorders (e.g., depression, schizophrenia, alcohol addiction, or drug addiction).
4. Receives concomitant treatment during the study, which can affect trial results (e.g., dementia treatment and sleeping pills).
5. Is illiterate.

## Randomization

Participants will be randomly allocated with a 1:1 ratio to receive treatment with the speech therapy application along with usual stroke care (the intervention group) or usual stroke care only (the control group). The randomization will be performed by the research officer (not involved in this study) of the clinical trial center of Seoul Hospital, Ewha Womans University. An Excel spreadsheet will be used to generate the random list. The randomization will be created using reasonably sized permuted blocks, and the block size will not be disclosed until the completion of the trial to ensure masking.

## Blinding

Due to the interactive nature of rehabilitation, it is not possible to mask the intervention to patients and research investigators. Therefore, we will blind the separate outcome assessors, who will not be involved in the treatment procedures, to minimize bias. In order to maintain blindness, participants will also be advised not to disclose their assigned group to the outcome assessors.

## Interventions

**Patients allocated to the control group** will receive "usual stroke care" including medical treatment and routine rehabilitation therapy for four weeks. Clinicians and speech-language pathologists will provide usual stroke care based on conventional stroke therapy guidelines [24, 25] and patient needs. This care is expected to be set according to clinical needs as agreed between clinicians and patients and modified according to progress. Participants in this group will only receive usual stroke care and will not use the mobile application, D-ST01.

**Participants in the intervention group** will use the speech therapy application, D-ST01, in addition to receiving usual stroke care (see S3). D-ST01 is a mobile application that delivers speech therapy to patients with post-stroke dysarthria, allowing them to rehabilitate independently. As repetitive and intensive training is crucial in speech therapy, the system

features gamification, tailored feedback, and interactive functions designed to motivate patients to persist with constant speech training. Ten different types of speech exercises are provided in the program, with the goal of enhancing speech intelligibility. Participants will perform the speech exercises for one hour per day, five days per week, for four consecutive weeks. They may complete the speech exercises all at once or split them into several sessions. The application provides both written and verbal instructions for each exercise in order to support participants with no or little experience in using a mobile application. The research team will help participants to install the application and will provide a practice session at baseline to enhance participants' understanding of and engagement with the intervention. Furthermore, participants will be encouraged to reach out to the research team if any issues arise regarding the use of the application.

## **Data collection**

The primary outcome will be indicated by changes in repeated measured data concerning speech intelligibility between the intervention group and control group from baseline to 4-weeks post-intervention.

Speech intelligibility will be assessed by reading "Gaeul" [26], a text commonly used to evaluate speech disorders in Korea. For future analysis and confirmation, all speech evaluations will be recorded using a high-quality digital recorder (SONY ICD-UX560F). Then, three researchers will listen to the continuous speech of participants and calculate the average by evaluating their intelligibility with a score of 0 (normal) to 6 (unintelligible) [27].

Secondary outcome measures will be evaluated at baseline and after 4 weeks. These will include percentage of consonants correct [28, 29], oral mechanism test [30], oral-diadochokinesis [31], maximum phonation time [32] and phonation evaluation [30]. The experienced speech-language pathologists (with a minimum experience of 6 years), blinded to the participants' allocation, will be asked to assess various aspects of participants' speech.

The tertiary outcome will be indicated by changes in a stroke scale and psychological scales. The qualified researchers will evaluate the National Institute of Health Stroke Scale [33]. In addition, we will evaluate patient-reported outcomes concerning depression (Patient Health Questionnaire-9) [34], anxiety (Generalized Anxiety disorder-7) [35], quality of life (Euro Quality of Life) [36], and self-efficacy (Modified Computer Self-Efficacy Scale) [37]. In the last phase of the study, the patients who used the application will complete a system usability scale questionnaire to uncover their experience with the smartphone-based speech therapy [38]. Details of the outcome measures are described in the S2 protocol file.

## **Analyses**

### **Sample size**

The purpose of this study protocol is to investigate the feasibility of digital speech therapy for post-stroke dysarthria, and the results will be used for future power analyses of a larger study. A power calculation was carried out by using G\*power 3.0 given the following: 1) power of 80%, 2) a two-sided alpha of 0.05, 3) an estimated effect size of 0.8, and 4) a 1:1 intervention allocation. Thus, each group will need a sample size of 26 participants. The effect size was calculated by referring to the results of the existing study. Moon and Won studied the effectiveness of smartphone-based speech exercises for 14 acute stroke patients [39]. As a result of calculating the power for the primary outcome with a significance level of 0.05 and 26 participants per group, the oral mechanism was 98%, and oral-diadochokinetic was 98%. Therefore, the use of a major primary outcome, oral mechanism [30], and oral-diadochokinetic [40, 41] for 52 participants are expected to be appropriate in this study. The power analysis is described in detail in S2 protocol file. A total of 60 participants (30 in each group) will be recruited, considering 15% dropout rate.

### **Statistical methods**



All analyses, including a descriptive analysis of demographic and outcome data, will be performed in SPSS (version 25; IBM New York).

An intention-to-treat analysis will be conducted in order to compare outcome measures. First, the Shapiro-Wilk test will be used to examine whether the distribution of continuous variables is normal. Depending on normality, a parametric test (which assumes normal distribution) or non-parametric equivalents (not satisfied with a normality distribution) will be performed. The general characteristics of the two groups will be analyzed with the independent t-test or the Mann-Whitney U test.

Next, paired comparison within the groups (pre- and post-intervention) will be analyzed using the paired t-test or the Wilcoxon signed-rank test. A repeated measures analysis of variance will be performed for each result, taking into account the within-subject factor time (Pre; Post) and the between-subject factor group (Intervention group; Control group). Moreover, a linear mixed model that controls for baseline National Institute of Health Stroke Scale and the location of cerebral infarction as fixed effects will be performed. Statistical significance will be set at  $p < 0.05$ . The Last Observation Carried Forward method [42] will be performed to manage the missing data.

## Monitoring

A data monitoring committee is not needed since there is no risk that mobile-based intervention content will adversely affect participants. Participants may withdraw consent at any time for any reason. Should participants withdraw, they can discontinue the trial without any consequences. Additionally, if a participant requires immediate medical attention, the researchers may withdraw them from the trial.

## Discussion

Our protocol is for a randomized clinical trial of a digital therapeutic provided to stroke patients with dysarthria. Although intensive and repetitive speech therapy is recommended due to its apparent benefits, post-stroke dysarthria treatment remains under-researched [43, 44]. Insufficient methodological rigor, a paucity of studies, and a narrow scope of evaluated interventions limit the available evidence concerning dysarthria treatment [22, 45]. Several studies have adopted traditional speech interventions, including behavioral techniques, breathing, non-speech oro-motor exercises, Lee Silverman Voice Treatment, repetition training of sound, and progressive reading [46]. In a study by Mahler and Ramig [47], reading phrases and Lee Silverman Voice Treatment, which targets high phonatory effort to improve speech skills, were employed in the intervention. Four patients with dysarthria at nine months or more post-stroke received 16 one-hour sessions over four weeks and showed positive responses. Park et al.[48] verified the effect of speech therapy on patients at least six months post-onset of stroke. The intervention consisted of a 60-minute practice, four times per week, for four weeks (16 sessions). The treatment in this study focused on enhancing speech intelligibility with repetitive acoustic-phonetic adjustments.

As in previous studies, our intervention is based on traditional treatments that incorporate motor learning principles (rigorous repetitive training and feedback) [44] and neuroplasticity (repetition, motivation, and reward) [10]. In addition, the treatment duration of one hour, five times per week, for four weeks is consistent with previous behavioral interventions in post-stroke dysarthria [47-50]. However, our protocol differs in enrolling stroke patients from acute to subacute period. The prognosis of speech treatment in the first few months is important since the stroke onset could be critical to reducing recovery time [51]. Nonetheless, the evidence of post-stroke dysarthria in the acute phase is weak [52]. Therefore, the results of our protocol will prove whether the smartphone-based intervention used in this study can help stroke patients with dysarthria to improve their conditions in the acute to subacute period.

As traditional speech therapy continues to fall short of meeting the needs of dysarthric patients, the use of technology in speech rehabilitation has increased, providing new opportunities to overcome the limits of face-to-face treatments. As in all post-stroke rehabilitation, inadequate long-term adherence is a problem in speech therapy [53, 54]. Patients may exercise less frequently than suggested [55], struggle to achieve daily treatment goals [56], or even quit therapy entirely [54]. Digital therapeutics available in home settings are expected to promote high-intensity programs [8], which allow self-management of speech training, facilitate access to care, improve treatment engagement, and lower care costs [16, 57]. Despite the various advantages of technology-based speech therapy, evidence that such therapies are effective in patients with dysarthria is lacking. Our D-ST01 intervention is novel and innovative in that it is composed of several technical features to help with post-stroke dysarthria treatment. D-ST01 adopts gamification elements, responding to users' speech in real-time and providing points for each task. Since adherence to rehabilitation in stroke patients remains an unmet need, the gamified intervention can make training more enjoyable. As a result, patients' increased intrinsic motivation can lead to treatment engagement [58, 59]. Technology also enables accurate measurement of several parameters of user interactions and generates valuable feedback to improve the performance of goal-oriented tasks [60]. Participants in this study will receive real-time performance feedback for each exercise (e.g., "Speak louder!"), as well as summary feedback on a daily and weekly basis. The use of this personalized feedback structure is in line with previous findings [44, 61], which indicate that it reinforces positive behaviors and enhances performance. Therefore, the goal of this randomized controlled clinical trial is to identify the feasibility of a smartphone-based post-stroke dysarthria treatment that incorporates gamification, tailored feedback, and interactive functions.

This protocol has a few limitations. First, although this is a pilot trial, the sample size is small. Therefore, generalization may be limited. Second, participants do not receive face-to-face

treatment during the intervention. Under these circumstances, patients' motivation might decrease due to the lack of interpersonal interaction, resulting in a higher-than-expected dropout rate [54, 60]. To address this limitation, we will monitor user data periodically and manage participants through intermittent phone coaching and messaging in order to reduce the number of dropouts. Third, since our D-ST01 app runs only in Korean, the result of the study may not be applicable to stroke patients in other countries. In addition, the study has limited generalizability to the population of patients who are incapable of using or accessing smartphone technology. This issue is particularly prevalent in the elderly population, which is the main target of our study, given that people over 60 account for the majority of stroke cases [61]. However, the findings of this study will form a basis for understanding elderly stroke patients and developing future speech rehabilitation programs for the aging population. Despite these limitations, the findings from this study will inform decisions about effect size estimates and power analysis in future studies.

## **Dissemination**

Our study protocol will convey key findings and implications to stakeholders related to digital therapeutics for post-stroke dysarthria. The results will be used as evidence for large-scale clinical trials in the future and will be submitted and published in peer-reviewed scientific journals and global conferences.

## **Supporting information**

**S1 Checklist. SPIRT 2013 checklist.**

(DOCX)

**S2 Protocol.**

(DOCX)

**S3 TIDieR checklist.**

273 (DOCX)

## 274 **Author contributions**

275 **Conceptualization:** Yuyoung Kim, Minjung Kim, Tae-Jin Song

276 **Methodology:** Yuyoung Kim, Minjung Kim, Tae-Jin Song

277 **Writing – original draft:** Yuyoung Kim, Minjung Kim

278 **Writing – review & editing:** Yuyoung Kim, Minjung Kim, Tae-Jin Song

279 **Supervision:** Yuyoung Kim, Minjung Kim, Tae-Jin Song, Jinwoo Kim

## 280 **References**

281 1. Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, et al. World Stroke

282 Organization (WSO): Global Stroke Fact Sheet 2022. International Journal of Stroke.

283 2022;17(1):18-29. doi: 10.1177/17474930211065917. PubMed PMID: 34986727.

284 2. Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-Related Quality of

285 Life Among Long-Term Survivors of Stroke. Stroke. 2000;31(2):440-7. doi:

286 doi:10.1161/01.STR.31.2.440.

287 3. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Anderson CS. Long-term disability after

288 first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989-

289 1990. Stroke. 2002;33(4):1034-40. doi: 10.1161/01.str.0000012515.66889.24. PubMed

290 PMID: 11935057.

291 4. Flowers HL, Silver FL, Fang J, Rochon E, Martino R. The incidence, co-occurrence, and

292 predictors of dysphagia, dysarthria, and aphasia after first-ever acute ischemic stroke. Journal

293 of communication disorders. 2013;46(3):238-48. Epub 20130412. doi:

294 10.1016/j.jcomdis.2013.04.001. PubMed PMID: 23642855.

295 5. Duffy JR. Motor speech disorders : substrates, differential diagnosis, and management.  
 296 Fourth edition. ed. St. Louis, Missouri: Elsevier; 2020.

297 6. Pamela Comrie CMJM. The influence of acquired dysarthria on conversational turn-  
 298 taking. *Clinical Linguistics & Phonetics*. 2001;15(5):383-98. doi:  
 299 10.1080/02699200110036380.

300 7. Mackenzie C, Kelly S, Paton G, Brady M, Muir M. The Living with Dysarthria group for  
 301 post-stroke dysarthria: the participant voice. *International journal of language &*  
 302 *communication disorders*. 2013;48(4):402-20. Epub 20130417. doi: 10.1111/1460-  
 303 6984.12017. PubMed PMID: 23889836.

304 8. Dickson S, Barbour RS, Brady M, Clark AM, Paton G. Patients' experiences of disruptions  
 305 associated with post-stroke dysarthria. *International Journal of Language & Communication*  
 306 *Disorders*. 2008;43(2):135-53. doi: 10.1080/13682820701862228. PubMed PMID:  
 307 18283594.

308 9. Mitchell C, Bowen A, Tyson S, Conroy P. A feasibility randomized controlled trial of  
 309 ReaDySpeech for people with dysarthria after stroke. *Clinical Rehabilitation*.  
 310 2018;32(8):1037-46. Epub 20171226. doi: 10.1177/0269215517748453. PubMed PMID:  
 311 29278019; PubMed Central PMCID: PMC6088453.

312 10. Kiran S, Thompson CK. Neuroplasticity of Language Networks in Aphasia: Advances,  
 313 Updates, and Future Challenges. *Frontiers in Neurology*. 2019;10:295. Epub 20190402. doi:  
 314 10.3389/fneur.2019.00295. PubMed PMID: 31001187; PubMed Central PMCID:  
 315 PMC6454116.

316 11. Robertson SJ, Thomson F. Speech therapy in Parkinson's disease: a study of the efficacy  
 317 ad long term effects of intensive treatment. *British Journal of Disorders of Communication*.  
 318 1984;19(3):213-24. doi: 10.3109/13682828409029837. PubMed PMID: 6508992.

319 12. Tamayo-Serrano P, Garbaya S, Bouakaz S, Blazevic P. A Game-Based Rehabilitation  
320 Therapy for Post-Stroke Patients: An Approach for Improving Patient Motivation and  
321 Engagement. IEEE Systems, Man, and Cybernetics Magazine. 2020;6(4):54-62. doi:  
322 10.1109/MSMC.2020.3002519.

323 13. Avan A, Digaleh H, Di Napoli M, Stranges S, Behrouz R, Shojaeianbabaei G, et al.  
324 Socioeconomic status and stroke incidence, prevalence, mortality, and worldwide burden: an  
325 ecological analysis from the Global Burden of Disease Study 2017. BMC Med.  
326 2019;17(1):191. Epub 20191024. doi: 10.1186/s12916-019-1397-3. PubMed PMID:  
327 31647003; PubMed Central PMCID: PMC6813111.

328 14. Dobkin BH, Dorsch A. New evidence for therapies in stroke rehabilitation. Current  
329 atherosclerosis reports. 2013;15(6):1-9. doi: 10.1007/s11883-013-0331-y. PubMed PMID:  
330 23591673; PubMed Central PMCID: PMC3679365.

331 15. Fairburn CG, Patel V. The impact of digital technology on psychological treatments and  
332 their dissemination. Behaviour Research and Therapy. 2017;88:19-25. doi:  
333 <https://doi.org/10.1016/j.brat.2016.08.012>.

334 16. Abbadessa G, Brigo F, Clerico M, De Mercanti S, Trojsi F, Tedeschi G, et al. Digital  
335 therapeutics in neurology. Journal of Neurology. 2022;269(3):1209-24. Epub 20210520. doi:  
336 10.1007/s00415-021-10608-4. PubMed PMID: 34018047; PubMed Central PMCID:  
337 PMC68136262.

338 17. Tăut D, Pinteș S, Roovers J-PWR, Mañanas M-A, Băban A. Play seriously: Effectiveness  
339 of serious games and their features in motor rehabilitation. A meta-analysis.  
340 NeuroRehabilitation. 2017;41:105-18. doi: 10.3233/NRE-171462.

341 18. Fu MJ, Knutson JS, Chae J. Stroke Rehabilitation Using Virtual Environments. Physical  
342 Medicine and Rehabilitation Clinics. 2015;26(4):747-57. doi: 10.1016/j.pmr.2015.06.001.

19. Valentin LSS. Can Digital Games Be a Way of Improving the Neuroplasticity in Stroke Damage? Can the Adult Brain Grow New Cells or Rewire Itself in Response to a New Experience? Open Journal of Medical Psychology. 2017;6(2):153-65. doi: 10.4236/ojmp.2017.62013.
20. Suchak P, Ameer K, Gaylard J, Newman J, Ali K. Improving patients experience in a neuro-rehabilitation unit using tablet computers. European Journal for Person Centered Healthcare. 2016;4(2):289-95. doi: <http://dx.doi.org/10.5750/ejpch.v4i2.1082>.
21. Macoir J, Lavoie M, Routhier S, Bier N. Key Factors for the Success of Self-Administered Treatments of Poststroke Aphasia Using Technologies. Telemedicine and e-Health. 2019;25(8):663-70. doi: 10.1089/tmj.2018.0116. PubMed PMID: 30142032.
22. Mitchell C, Bowen A, Tyson S, Butterfint Z, Conroy P. Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury. Cochrane Database of Systematic Reviews. 2017;(1). doi: 10.1002/14651858.CD002088.pub3. PubMed PMID: CD002088.
23. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4. doi: 10.1001/jama.2013.281053. PubMed PMID: 24141714.
24. Ko SB, Park HK, Kim BM, Heo JH, Rha JH, Kwon SU, et al. 2019 Update of the Korean Clinical Practice Guidelines of Stroke for Endovascular Recanalization Therapy in Patients with Acute Ischemic Stroke. Journal of stroke. 2019;21(2):231-40. Epub 20190417. doi: 10.5853/jos.2019.00024. PubMed PMID: 30991800; PubMed Central PMCID: PMCPMC6549067.
25. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke



368 Association. Stroke. 2021;52(7):e364-e467. Epub 20210524. doi:  
369 10.1161/STR.0000000000000375. PubMed PMID: 34024117.

370 26. Kim HH, editor Perceptual, acoustical, and physiological tools in ataxic dysarthria  
371 management: a case report. Proceedings of the KSPS conference; 1996: The Korean Society  
372 Of Phonetic Sciences And Speech Technology.

373 27. Lousada M, Jesus LMT, Hall A, Joffe V. Intelligibility as a clinical outcome measure  
374 following intervention with children with phonologically based speech–sound disorders.  
375 International Journal of Language & Communication Disorders. 2014;49(5):584-601. doi:  
376 <https://doi.org/10.1111/1460-6984.12095>.

377 28. Kim YT, Park H, Kang JK, Kim JA, Shin MJ, Kim S-J, et al. Validity and reliability  
378 analyses for the development of Urimal Test of Articulation and Phonology-2.  
379 Communication Sciences & Disorders. 2018;23(4):959-70. doi: 10.12963/csd.18545.

380 29. Namasivayam AK, Huynh A, Granata F, Law V, van Lieshout P. PROMPT intervention  
381 for children with severe speech motor delay: a randomized control trial. Pediatric Research.  
382 2021;89(3):613-21. Epub 20200501. doi: 10.1038/s41390-020-0924-4. PubMed PMID:  
383 32357364; PubMed Central PMCID: PMC7979536.

384 30. Shin MJ, Kim, J. O., Lee, S. B., & Lee, S. Y. Speech mechanism screening test. Seoul:  
385 Hakjisa; 2010.

386 31. Ziegler W. Task-related factors in oral motor control: speech and oral diadochokinesis in  
387 dysarthria and apraxia of speech. Brain and language. 2002;80(3):556-75. doi:  
388 10.1006/brln.2001.2614. PubMed PMID: 11896657.

389 32. Kwon YG, Do KH, Park SJ, Chang MC, Chun MH. Effect of Repetitive Transcranial  
390 Magnetic Stimulation on Patients With Dysarthria After Subacute Stroke. Annals of  
391 rehabilitation medicine,. 2015;39(5):793-9. Epub 20151026. doi: 10.5535/arm.2015.39.5.793.  
392 PubMed PMID: 26605178; PubMed Central PMCID: PMC7979536.

33. Oh MS, Yu K-H, Lee J-H, Jung S, Ko I-S, Shin J-H, et al. Validity and Reliability of a Korean Version of the National Institutes of Health Stroke Scale. *Journal of Clinical Neurology*. 2012;8(3):177-83. doi: 10.3988/jcn.2012.8.3.177.

34. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. *Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire*. *JAMA*. 1999;282(18):1737-44. doi: 10.1001/jama.282.18.1737. PubMed PMID: 10568646.

35. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Archives of internal medicine*. 2006;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. PubMed PMID: 16717171.

36. Lee Y-K, Nam H-S, Chuang L-H, Kim K-Y, Yang H-K, Kwon I-S, et al. South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. *Value in health*. 2009;12(8):1187-93. doi: 10.1111/j.1524-4733.2009.00579.x.

37. Compeau DR, Higgins CA. Computer Self-Efficacy: Development of a Measure and Initial Test. *MIS Quarterly*. 1995;19(2):189-211. doi: 10.2307/249688.

38. Brooke JB, editor SUS: A 'Quick and Dirty' Usability Scale 1996.

39. Moon j-H, Won Y-S. The Effects of Orofacial Exercises Program using Smart Phone on Swallowing Function and Tongue Strength in Acute Stroke Patients with Dysphagia. *The Journal of the Korea Institute of Electronic Communication Sciences*. 2016;11(10):995-1002. doi: <https://doi.org/10.13067/JKIECS.2016.11.10.995>.

40. Wang YT, Kent RD, Duffy JR, Thomas JE. Analysis of Diadochokinesis in Ataxic Dysarthria Using the Motor Speech Profile Program™. *Folia Phoniatrica et Logopaedica*. 2009;61(1):1-11. doi: 10.1159/000184539.

41. Kent RD, Weismer G, Kent JF, Vorperian HK, Duffy JR. Acoustic studies of dysarthric speech: methods, progress, and potential. *Journal of communication disorders*. 1999;32(3):141-86. doi: 10.1016/s0021-9924(99)00004-0. PubMed PMID: 10382143.
42. Hamer RM, Simpson PM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. *American Journal of Psychiatry*. 2009;166(6):639-41. doi: 10.1176/appi.ajp.2009.09040458. PubMed PMID: 19487398.
43. Bislick LP, Weir PC, Spencer K, Kendall D, Yorkston KM. Do principles of motor learning enhance retention and transfer of speech skills? A systematic review. *Aphasiology*. 2012;26(5):709-28. doi: 10.1080/02687038.2012.676888.
44. Maas E, Robin DA, Hula SNA, Freedman SE, Wulf G, Ballard KJ, et al. Principles of motor learning in treatment of motor speech disorders. *American Journal of Speech-Language Pathology*. 2008;17(3):277-98. doi: [https://doi.org/10.1044/1058-0360\(2008/025\)](https://doi.org/10.1044/1058-0360(2008/025)).
45. Finch E, Rumbach AF, Park S. Speech pathology management of non-progressive dysarthria: a systematic review of the literature. *Disability and rehabilitation*. 2020;42(3):296-306. Epub 20181004. doi: 10.1080/09638288.2018.1497714. PubMed PMID: 30286661.
46. Chiaramonte R, Pavone P, Vecchio M. Speech rehabilitation in dysarthria after stroke: a systematic review of the studies. *Eur J Phys Rehabil Med*. 2020;56(5):547-62. Epub 20200519. doi: 10.23736/s1973-9087.20.06185-7. PubMed PMID: 32434313.
47. Mahler LA, Ramig LO. Intensive treatment of dysarthria secondary to stroke. *Clinical Linguistics & Phonetics*. 2012;26(8):681-94. doi: 10.3109/02699206.2012.696173.
48. Park S, Theodoros D, Finch E, Cardell E. Be Clear: A New Intensive Speech Treatment for Adults With Nonprogressive Dysarthria. *American Journal of Speech-Language Pathology*. 2016;25(1):97-110. doi: 10.1044/2015\_ajslp-14-0113. PubMed PMID: 26882004.

49. Wenke RJ, Cornwell P, Theodoros DG. Changes to articulation following LSVT® and traditional dysarthria therapy in non-progressive dysarthria. *International Journal of Speech-Language Pathology*. 2010;12(3):203-20. doi: 10.3109/17549500903568468.
50. Beijer LJ, Rietveld ACM, Ruiter MB, Geurts ACH. Preparing an E-learning-based Speech Therapy (EST) efficacy study: Identifying suitable outcome measures to detect within-subject changes of speech intelligibility in dysarthric speakers. *Clinical Linguistics & Phonetics*. 2014;28(12):927-50. doi: 10.3109/02699206.2014.936627.
51. Coleman ER, Moudgal R, Lang K, Hyacinth HI, Awosika OO, Kissela BM, et al. Early Rehabilitation After Stroke: a Narrative Review. *Current atherosclerosis reports*. 2017;19(12):1-12. Epub 20171107. doi: 10.1007/s11883-017-0686-6. PubMed PMID: 29116473; PubMed Central PMCID: PMC5802378.
52. Spencer KA, Brown KA, editors. *Dysarthria following stroke*. Seminars in speech and language; 2018: Thieme Medical Publishers.
53. Behrman A, Rutledge J, Hembree A, Sheridan S. Vocal hygiene education, voice production therapy, and the role of patient adherence: a treatment effectiveness study in women with phonotrauma. *Journal of Speech, Language, and Hearing Research*. 2008;51(2):350-66. doi: [https://doi.org/10.1044/1092-4388\(2008/026\)](https://doi.org/10.1044/1092-4388(2008/026)).
54. Hapner E, Portone-Maira C, Johns MM. A Study of Voice Therapy Dropout. *Journal of Voice*. 2009;23(3):337-40. doi: <https://doi.org/10.1016/j.jvoice.2007.10.009>.
55. van Leer E, Connor NP. Predicting and influencing voice therapy adherence using social-cognitive factors and mobile video. *American journal of speech-language pathology*. 2015;24(2):164-76. doi: [https://doi.org/10.1044/2015\\_AJSLP-12-0123](https://doi.org/10.1044/2015_AJSLP-12-0123).
56. van Leer E, Connor NP. Patient perceptions of voice therapy adherence. *Journal of Voice*. 2010;24(4):458-69. doi: <https://doi.org/10.1016/j.jvoice.2008.12.009>.

464 57. Kamoen O, Maqueda V, Yperzeele L, Pottel H, Cras P, Vanhooren G, et al. Stroke coach:  
465 a pilot study of a personal digital coaching program for patients after ischemic stroke. *Acta*  
466 *Neurologica Belgica*. 2020;120(1):91-7. Epub 20191107. doi: 10.1007/s13760-019-01218-z.  
467 PubMed PMID: 31701472.

468 58. Oyake K, Suzuki M, Otaka Y, Tanaka S. Motivational Strategies for Stroke  
469 Rehabilitation: A Descriptive Cross-Sectional Study. *Frontiers in neurology*. 2020;11:553.  
470 Epub 20200610. doi: 10.3389/fneur.2020.00553. PubMed PMID: 32587572; PubMed Central  
471 PMCID: PMCPMC7297944.

472 59. Bakker M, Beijer L, Rietveld T. Considerations on Effective Feedback in Computerized  
473 Speech Training for Dysarthric Speakers. *Telemedicine and e-Health*. 2019;25(5):351-8.  
474 Epub 20180803. doi: 10.1089/tmj.2018.0050. PubMed PMID: 30074851.

475 60. Ramsberger G, Marie B. Self-administered cued naming therapy: A single-participant  
476 investigation of a computer-based therapy program replicated in four cases. *American*  
477 *Journal of Speech-Language Pathology*. 2007;16(4):343-58. doi:  
478 [https://doi.org/10.1044/1058-0360\(2007/038\)](https://doi.org/10.1044/1058-0360(2007/038)).

479 61. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart  
480 Disease and Stroke Statistics—2022 Update: A Report From the American Heart  
481 Association. *Circulation*. 2022;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052.

TIMEPOINT	STUDY PERIOD				
	Enrolment	Allocation	Post-allocation		Close-out
	Pre-baseline	Pre-baseline	Baseline	4 weeks	Post-study
<b>ENROLMENT:</b>					
<i>Eligibility screen</i>	X				
<i>Informed consent</i>	X				
<i>Allocation</i>		X			
<b>INTERVENTIONS:</b>					
<i>Usual care</i>					
<i>D-ST01 + usual care</i>					
<b>ASSESSMENTS:</b>					
Speech intelligibility			X	X	
Percentage of consonants correct			X	X	
Oral mechanism			X	X	
Oral-diadochokinetic			X	X	
Voice measures			X	X	
National Institute of Health Stroke Scale			X	X	
Depression			X	X	
Anxiety			X	X	
Quality of Life			X	X	
Self-Efficacy			X	X	
System usability					X

medRxiv preprint doi: <https://doi.org/10.1101/2022.08.16.22278857>; this version posted August 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.




Fig2